Den ene var en ikke- sammenlignende undersøgelse hos 138 patienter (29% fik tidligere kemoterapi), og den anden var en randomiseret aktiv- kontrolleret undersøgelse med TMZ versus procarbazin hos i alt 225 patienter (67% fik tidligere behandling med nitrosurea baseret kemoterapi).
One was a non-comparative trial in 138 patients (29% received prior chemotherapy), and the other was a randomised active-controlled trial of TMZ vs procarbazine in a total of 225 patients (67% received prior treatment with nitrosourea based chemotherapy).